Difference between revisions of "Glioblastoma - null regimens"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =Adjuvant therapy= | ||
| + | ==Best supportive care== | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
| + | ===Regimen=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Dates of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1056/NEJMoa065901 Keime-Guibert et al. 2007] | ||
| + | |2001-2005 | ||
| + | | style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |[[Glioblastoma#Radiation_therapy_2|RT]] x 5000 cGy | ||
| + | | style="background-color:#d73027" |Inferior OS | ||
| + | |- | ||
| + | |} | ||
| + | ''No antineoplastic therapy after primary surgery.'' | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
| + | ====Preceding treatment==== | ||
| + | *[[Surgery#CNS_cancer_surgery|Surgery]] | ||
| + | </div></div> | ||
| + | ===References=== | ||
| + | #'''BTSG 69-01:''' Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333-43. [https://doi.org/10.3171/jns.1978.49.3.0333 link to original article] [https://pubmed.ncbi.nlm.nih.gov/355604/ PubMed] | ||
| + | #Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527-35. [https://doi.org/10.1056/NEJMoa065901 link to original article] [https://pubmed.ncbi.nlm.nih.gov/17429084/ PubMed] [https://clinicaltrials.gov/study/NCT00430911 NCT00430911] | ||
| + | |||
=Recurrent disease, non-curative therapy= | =Recurrent disease, non-curative therapy= | ||
==Placebo {{#subobject:3fdb9e|Regimen=1}}== | ==Placebo {{#subobject:3fdb9e|Regimen=1}}== | ||
| Line 31: | Line 58: | ||
|} | |} | ||
''No active antineoplastic treatment.'' | ''No active antineoplastic treatment.'' | ||
| + | </div> | ||
===References=== | ===References=== | ||
#Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC; Polymer-Brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr 22;345(8956):1008-12. [https://doi.org/10.1016/s0140-6736(95)90755-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7723496/ PubMed] | #Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC; Polymer-Brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr 22;345(8956):1008-12. [https://doi.org/10.1016/s0140-6736(95)90755-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7723496/ PubMed] | ||
| − | #Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 Apr;5(2):79-88. [https:// | + | #Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 Apr;5(2):79-88. [https://doi.org/10.1093/neuonc/5.2.79 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920672/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/12672279/ PubMed] |
[[Category:Glioblastoma regimens]] | [[Category:Glioblastoma regimens]] | ||
Latest revision as of 23:29, 30 June 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main GBM page for regimens that include active anticancer treatment.
Adjuvant therapy
Best supportive care
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Keime-Guibert et al. 2007 | 2001-2005 | Phase 3 (C) | RT x 5000 cGy | Inferior OS |
No antineoplastic therapy after primary surgery.
Preceding treatment
References
- BTSG 69-01: Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333-43. link to original article PubMed
- Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527-35. link to original article PubMed NCT00430911
Recurrent disease, non-curative therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Brem et al. 1995 | 1989-1992 | Phase 3 (C) | Gliadel wafer | Inferior OS |
| Westphal et al. 2003 | 1997-1999 | Phase 3 (C) | Gliadel wafer | Seems to have inferior OS |
No active antineoplastic treatment.
References
- Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC; Polymer-Brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr 22;345(8956):1008-12. link to original article PubMed
- Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 Apr;5(2):79-88. link to original article link to PMC article PubMed